Core Focus
Achieving successful out-licensing and commercial readiness for European and US biotech assets in China/APAC.
Ideal For
Innovative biotech companies with clinical-stage assets, seeking to partner with leading Chinese/APAC biotech and pharmaceutical companies.
Our Approach
Redefining Out-Licensing: Speed, New Niche, Global, Revenue
Given the resources we’ve accumulated through our 20+ years of experience in the APAC market and its burgeoning biotech industry, we believe out-licensing to the APAC market should achieve more than just a BD deal. Within an out-licensing deal, we fully leverage the local R&D infrastructure – scientific, clinical, and medical resources – to discover niche indication(s) and region-specific differentiation to further drive valuation.At JRC, our goal is asset value maximization – helping clients uncover the hidden value of an asset. We strategically structure the deal in a way such that out-licensing is not only an immediate revenue stream but also creates new possibilities for the asset. Doing so requires a truly capable, synergistic biotech/pharma partner and access to the right resources. Our platforms are built to execute just that:
BioAccess Platform
Finding a truly synergistic partner, advancing into TS in just months.
- Network of hundreds of active biotech and pharma buyers
- Access to 100% of Tier 1 hospitals
- Access to local vendors and selection evaluation based on client needs
An extensive network is just a tool. Our unique expertise lies in identifying a truly synergistic APAC partner and pushing for value excavation through deal structuring and negotiation. We have both the tool and the expertise.
Integrated Product Development (IPD) Engine
The IPD Engine is our second tool. Excavating hidden value requires directions and resources; the IPD Engine integrates global regulatory, product development mapping, stakeholder engagement, R&D resources and more to guide the discovery of new niches.
Through our differentiated out-licensing approach, we help clients secure partnerships quickly and improve asset valuation, strengthening the value of the remaining rights and positioning for greater heights.